|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
THIAZIDES AND OTHER DIURETICS, TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
FIBROZILS MAY DISPLACE THE DRUG FROM THEIR PROTEIN BINDING SITES, HENCE INCREASE THEIR PLASMA CONCENTRATION. SO DOSE OF THE DRUG SHOULD BE REDUCED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
THIAZIDES AND OTHER DIURETICS, TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
THIAZIDES AND OTHER DIURETICS, TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
THIAZIDES AND OTHER DIURETICS, TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
SYMPATHOMIMETICS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
KETOTIFEN CAN CAUSE REVERSIBLE FALL IN PLATELET COUNT WHEN CO-ADMINISTERED WITH ORAL ANTIDIABETICS
|
BETABLOCKERS CAN BOTH INCREASE HYPOGLYCEMIA & MASK THE TYPICAL SYMPATHETIC HYPOGLYCEMIC WARNING SIGNS
|
SYMPATHOMIMETICS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
SYMPATHOMIMETICS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
SYMPATHOMIMETICS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
SYMPATHOMIMETICS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
SYMPATHOMIMETICS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
SYMPATHOMIMETICS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
OESTROGENS REDUCE THE HYPOGLYCEMIC EFFECTS OF ANTIDIABETICS
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
BETABLOCKERS CAN BOTH INCREASE HYPOGLYCEMIA & MASK THE TYPICAL SYMPATHETIC HYPOGLYCEMIC WARNING SIGNS
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
SYMPATHOMIMETICS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
ALBENDAZOLE ACTION IS POTENTIATED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
PROGESTERONES TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
THIAZIDES AND OTHER DIURETICS, TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
BETABLOCKERS CAN BOTH INCREASE HYPOGLYCEMIA & MASK THE TYPICAL SYMPATHETIC HYPOGLYCEMIC WARNING SIGNS
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
THIAZIDES AND OTHER DIURETICS, TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
BETABLOCKERS CAN BOTH INCREASE HYPOGLYCEMIA & MASK THE TYPICAL SYMPATHETIC HYPOGLYCEMIC WARNING SIGNS
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
SYMPATHOMIMETICS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
OESTROGENS REDUCE THE HYPOGLYCEMIC EFFECTS OF ANTIDIABETICS
|
OESTROGENS REDUCE THE HYPOGLYCEMIC EFFECTS OF ANTIDIABETICS
|
SYNERGISTIC HYPOGLYCAEMIC EFFECT IS SEEN
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
OESTROGENS REDUCE THE HYPOGLYCEMIC EFFECTS OF ANTIDIABETICS
|
BETABLOCKERS CAN BOTH INCREASE HYPOGLYCEMIA & MASK THE TYPICAL SYMPATHETIC HYPOGLYCEMIC WARNING SIGNS
|
MICONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
SYMPATHOMIMETICS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
SYMPATHOMIMETICS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
SYMPATHOMIMETICS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
OCTREOTIDE ABSORPTION IS REDUCED BY THE DRUG
|
OESTROGENS REDUCE THE HYPOGLYCEMIC EFFECTS OF ANTIDIABETICS
|
OESTROGENS REDUCE THE HYPOGLYCEMIC EFFECTS OF ANTIDIABETICS
|
OESTROGENS REDUCE THE HYPOGLYCEMIC EFFECTS OF ANTIDIABETICS
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
BETABLOCKERS CAN BOTH INCREASE HYPOGLYCEMIA & MASK THE TYPICAL SYMPATHETIC HYPOGLYCEMIC WARNING SIGNS
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BETABLOCKERS CAN BOTH INCREASE HYPOGLYCEMIA & MASK THE TYPICAL SYMPATHETIC HYPOGLYCEMIC WARNING SIGNS
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
SYMPATHOMIMETICS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
THIAZIDES AND OTHER DIURETICS, TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
BETABLOCKERS CAN BOTH INCREASE HYPOGLYCEMIA & MASK THE TYPICAL SYMPATHETIC HYPOGLYCEMIC WARNING SIGNS
|
BETABLOCKERS CAN BOTH INCREASE HYPOGLYCEMIA & MASK THE TYPICAL SYMPATHETIC HYPOGLYCEMIC WARNING SIGNS
|